<DOC>
	<DOCNO>NCT02786901</DOCNO>
	<brief_summary>Loteprednol Etabonate Ophthalmic Gel , ( BID TID ) versus Vehicle Group Treatment Ocular Inflammation Pain Following Cataract Surgery .</brief_summary>
	<brief_title>LE Gel Treatment Ocular Inflammation Pain Following Cataract Surgery</brief_title>
	<detailed_description>A Phase 3 , Multi-Center , Double-Masked , Vehicle Controlled , Randomized , Parallel-Group Study Assess Loteprednol Etabonate Ophthalmic Gel , ( BID TID ) versus Vehicle Group Treatment Ocular Inflammation Pain Following Cataract Surgery .</detailed_description>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Loteprednol Etabonate</mesh_term>
	<criteria>Key 1 . Be 18 year old date Informed Consent Form ( ICF ) sign capacity provide voluntary informed consent . 2 . Be able read , understand , provide write informed consent Institutional Review Board ( IRB ) /Ethics Committee ( EC ) approve ICF provide Health Insurance Portability Accountability Act ( HIPAA ) authorization . 3 . Be willing able comply treatment followup/study procedure . 4 . Be candidate routine , uncomplicated cataract surgery ( phacoemulsification posterior chamber intraocular lens [ IOL ] implantation , combine surgery ) . 5 . In Investigator 's opinion , potential postoperative pinholed Snellen visual acuity ( VA ) least 20/200 study eye Visit 1 ( Screening ) least 20/200 fellow eye . Key 1 . Have severe/serious ocular condition history/presence chronic generalize systemic disease Investigator feel might increase risk subject confound result ( ) study . 2 . Be female subject pregnant breastfeeding . 3 . Be monocular ( fellow eye nonfunctional fellow eye 's pinhole vision bad Snellen 20/200 ) . 4 . Have ocular surgery ( include laser surgery ) study eye within 3 month fellow eye within 2 week prior Visit 1 ( Screening ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>